245 related articles for article (PubMed ID: 31711337)
21. Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis.
Luo Q; Xiao Z; Peng L
Hematology; 2021 Dec; 26(1):663-669. PubMed ID: 34493151
[TBL] [Abstract][Full Text] [Related]
22. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Sekhri R; Sadjadian P; Becker T; Kolatzki V; Huenerbein K; Meixner R; Marchi H; Wallmann R; Fuchs C; Griesshammer M; Wille K
Ann Hematol; 2021 Nov; 100(11):2707-2716. PubMed ID: 34462786
[TBL] [Abstract][Full Text] [Related]
23. Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
Shi D; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
Leuk Lymphoma; 2021 Nov; 62(11):2703-2715. PubMed ID: 34098836
[TBL] [Abstract][Full Text] [Related]
24. Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
Sakiyama E; Chinen Y; Tsukamoto T; Takimoto-Shimomura T; Kuwahara-Ota S; Matsumura-Kimoto Y; Shimura Y; Kobayashi T; Horiike S; Kuroda J
Infect Drug Resist; 2020; 13():1017-1021. PubMed ID: 32308443
[TBL] [Abstract][Full Text] [Related]
25. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
[TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
Mesa RA
IDrugs; 2010 Jun; 13(6):394-403. PubMed ID: 20506062
[TBL] [Abstract][Full Text] [Related]
29. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Barbui T; Vannucchi AM; Alvarez-Larran A; Iurlo A; Masciulli A; Carobbio A; Ghirardi A; Ferrari A; Rossi G; Elli E; Andrade-Campos MM; Kabat MG; Kiladjian JJ; Palandri F; Benevolo G; Garcia-Gutierrez V; Fox ML; Foncillas MA; Morcillo CM; Rumi E; Osorio S; Papadopoulos P; Bonifacio M; Cervantes KSQ; Serrano MS; Carreno-Tarragona G; Sobas MA; Lunghi F; Patriarca A; Elorza BN; Angona A; Mazo EM; Koschmieder S; Ruggeri M; Cuevas B; Hernandez-Boluda JC; Abadia EL; Cirici BX; Guglielmelli P; Garrote M; Cattaneo D; Daffini R; Cavalca F; Bellosillo B; Benajiba L; Curto-Garcia N; Bellini M; Betti S; De Stefano V; Harrison C; Rambaldi A
Leukemia; 2021 Feb; 35(2):485-493. PubMed ID: 33414483
[TBL] [Abstract][Full Text] [Related]
30. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.
Adesola AA; Cozma MA; Chen YF; Srichawla BS; Găman MA
World J Hepatol; 2023 Nov; 15(11):1188-1195. PubMed ID: 38075009
[TBL] [Abstract][Full Text] [Related]
31. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T; Tefferi A; Vannucchi AM; Passamonti F; Silver RT; Hoffman R; Verstovsek S; Mesa R; Kiladjian JJ; Hehlmann R; Reiter A; Cervantes F; Harrison C; Mc Mullin MF; Hasselbalch HC; Koschmieder S; Marchetti M; Bacigalupo A; Finazzi G; Kroeger N; Griesshammer M; Birgegard G; Barosi G
Leukemia; 2018 May; 32(5):1057-1069. PubMed ID: 29515238
[TBL] [Abstract][Full Text] [Related]
32. Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
Pepe S; Rossi E; Trawinska M; Tatarelli C; Di Veroli A; Maurillo L; Romano A; Crescenzi SL; di Toritto TC; Tafuri A; Latagliata R; Scalzulli E; Andriani A; De Stefano V; Breccia M
Ann Hematol; 2022 Jun; 101(6):1275-1282. PubMed ID: 35318505
[TBL] [Abstract][Full Text] [Related]
33. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Pieri L; Paoli C; Arena U; Marra F; Mori F; Zucchini M; Colagrande S; Castellani A; Masciulli A; Rosti V; De Stefano V; Betti S; Finazzi G; Ferrari ML; Rumi E; Ruggeri M; Nichele I; Guglielmelli P; Fjerza R; Mannarelli C; Fanelli T; Merli L; Corbizi Fattori G; Massa M; Cimino G; Rambaldi A; Barosi G; Cazzola M; Barbui T; Vannucchi AM
Am J Hematol; 2017 Feb; 92(2):187-195. PubMed ID: 27880982
[TBL] [Abstract][Full Text] [Related]
35. Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Rastrelli M; Ferrazzi B; Tropea S; Costa A; Finotto S; Marino D; Campana L; Del Fiore P; Rossi CR; Alaibac M
In Vivo; 2019; 33(5):1667-1669. PubMed ID: 31471421
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.
Marchetti M; Salmanton-García J; El-Ashwah S; Verga L; Itri F; Ráčil Z; Dávila-Valls J; Martín-Pérez S; Van Doesum J; Passamonti F; Abu-Zeinah G; Farina F; López-García A; Dragonetti G; Cattaneo C; Gomes Da Silva M; Bilgin YM; Žák P; Petzer V; Glenthøj A; Espigado I; Buquicchio C; Bonuomo V; Prezioso L; Meers S; Duarte R; Bergantim R; Jaksic O; Čolović N; Blennow O; Cernan M; Schönlein M; Samarkos M; Mitra ME; Magliano G; Maertens J; Ledoux MP; Jiménez M; Demirkan F; Collins GP; Cabirta A; Gräfe SK; Nordlander A; Wolf D; Arellano E; Cordoba R; Hanakova M; Zambrotta GPM; Nunes Rodrigues R; Limberti G; Marchesi F; Cornely OA; Pagano L
Ther Adv Hematol; 2023; 14():20406207231154706. PubMed ID: 36923264
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
38. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
[TBL] [Abstract][Full Text] [Related]
40. Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms.
Duan MH; Cao XX; Chang L; Zhou DB
Hematology; 2021 Dec; 26(1):460-464. PubMed ID: 34184610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
